세포 및 유전자 치료 CDMO 시장 규모, 점유율 및 동향 분석 보고서 : 단계별, 제품 유형별, 적응증별, 지역별, 부문별 예측(2024-2030년)

Cell And Gene Therapy CDMO Market Growth & Trends:

The global cell and gene therapy CDMO market size is expected to reach USD 27.45 billion by 2030 and is projected to grow at a CAGR of 27.9% from 2024 to 2030, according to a new report by Grand View Research, Inc.Growing research and development activities in cell and gene therapies, heightened focus on addressing rare diseases, the expanding pipeline of innovative products, a rising need for outsourced services in this field, and continuous technological advancements in the development processes are few of the factors collectively contribute to rising demand for the market.

Furthermore, increasing investments and funding from private and public sectors to develop novel cell and gene therapeutics is another significant factor supporting the market growth. A few of the notable examples of investments and funding in the cell and gene therapy market are mentioned below:

• In August 2021 SeQure Dx, a company specializing in gene editing diagnostics, announced a series A funding round of USD 17.5 million to develop gene therapeutics. This funding was led by Mass General Brigham Ventures and RiverVest Venture Partners, along with Casdin Capital, Digitalis Ventures, KdT Ventures, Alexandria Venture Investments, and Bold Capital Partners
• In August 2021, Eyevensys, a clinical-stage biotechnology company focusing on nonviral gene therapies for ophthalmic diseases, secured USD 12 million in a series B plus funding round

The initial phase of the COVID-19 pandemic adversely affected the market. The slowdown in overall clinical trial activity was a significant factor, primarily due to concerns about the safety of participants and staff, leading to delays and temporary suspensions. The disruption in supply chain management, particularly in transportation and logistics, posed challenges, and the uncertainty surrounding the pandemic created a general lack of demand forecast and feasibility planning. However, the market recovered through a combination of adapting to new norms, enhancing the resilience of supply chains, and implementing safety measures to navigate the challenges posed by the pandemic. Moreover, mergers and acquisition strategies adopted by the major companies have helped mitigate the negative impact of the pandemic by 2021.

Cell And Gene Therapy CDMO Market Report Highlights:

• The pre-clinical segment accounted for the largest share of 66.2% in 2023. The increasing pipeline of cell and gene therapeutics is one of the major factors supporting the segment's growth
• Based on the product type, the cell therapy segment accounted for the largest share of 41.6% in 2023. Cell therapy services are vital in advancing regenerative medicine & personalized medicine
• Rare diseases are anticipated to witness the highest CAGR of 28.4% across the analysis period. The growing prevalence of several rare diseases has led to a surge in R&D activities in cell and gene therapies, thus supporting segmental growth
• Asia Pacific is anticipated to witness the highest CAGR of 29.0% during the forecast time frame. The region's substantial growth is primarily attributed to the cost-effective manufacturing of cell and gene products due to lower labor and operational costs in several Asian economies

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Definitions
  • 1.1.2. Phase
  • 1.1.3. Product Type
  • 1.1.4. Indication
• 1.2. Regional Scope
• 1.3. Estimates And Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective - 1
  • 1.4.2. Objective - 2
  • 1.4.3. Objective - 3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information Or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. Parent Market Analysis
• 1.10. List Of Secondary Sources
• 1.11. List Of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Cell and Gene Therapy CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Growing pipeline of cell and gene therapy products to boost the market growth
    • 3.2.1.2. Increasing investments and R&D funding for the development of cell and gene therapeutics
    • 3.2.1.3. Technological innovations across the cell & gene therapy development process
    • 3.2.1.4. Increasing mergers & acquisitions in the cell and gene therapy industry
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance with strict regulatory requirements
    • 3.2.2.2. High development costs of CGT products
• 3.3. Cell and Gene Therapy CDMO Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat Of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Cell and Gene Therapy CDMO Market: Phase Estimates & Trend Analysis

• 4.1. Cell and Gene Therapy CDMO Market, By Phase: Segment Dashboard
• 4.2. Cell and Gene Therapy CDMO Market, By Phase: Movement Analysis
• 4.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Phase, 2018 - 2030
  • 4.3.1. Pre-clinical
    • 4.3.1.1. Pre-clinical Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
  • 4.3.2. Clinical
    • 4.3.2.1. Clinical Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)

Chapter 5. Cell and Gene Therapy CDMO Market: Product Type Estimates & Trend Analysis

• 5.1. Cell and Gene Therapy CDMO Market, By Product Type: Segment Dashboard
• 5.2. Cell and Gene Therapy CDMO Market, By Product Type: Movement Analysis
• 5.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Product Type, 2018 - 2030
  • 5.3.1. Gene Therapy
    • 5.3.1.1. Gene Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.1.2. Ex-vivo
    • 5.3.1.2.1. Ex-vivo Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.1.3. In-vivo
    • 5.3.1.3.1. In-vivo Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
  • 5.3.2. Gene-Modified Cell Therapy
    • 5.3.2.1. Gene-Modified Cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.2.2. CAR T-cell therapies
    • 5.3.2.2.1. CAR T-cell therapies Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.2.3. CAR-NK cell therapy
    • 5.3.2.3.1. CAR-NK cell therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.2.4. TCR-T cell therapy
    • 5.3.2.4.1. TCR-T cell therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
    • 5.3.2.5. Others
    • 5.3.2.5.1. Others cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)
  • 5.3.3. Cell Therapy
    • 5.3.3.1. Cell Therapy Cell and Gene Therapy CDMO Market, 2018 to 2030 (USD Million)

Chapter 6. Cell and Gene Therapy CDMO Market: Indication Estimates & Trend Analysis

• 6.1. Cell and Gene Therapy CDMO Market, By Indication: Segment Dashboard
• 6.2. Cell and Gene Therapy CDMO Market, By Indication: Movement Analysis
• 6.3. Cell and Gene Therapy CDMO Market Estimates & Forecasts, By Indication, 2018 - 2030
  • 6.3.1. Oncology
    • 6.3.1.1. Oncology Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
  • 6.3.2. Infectious Diseases
    • 6.3.2.1. Infectious Diseases Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
  • 6.3.3. Neurological Disorders
    • 6.3.3.1. Neurological Disorders Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
  • 6.3.4. Rare Diseases
    • 6.3.4.1. Rare Diseases Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)
  • 6.3.5. Others
    • 6.3.5.1. Others Cell and Gene Therapy CDMO Market 2018 to 2030 (USD Million)

Chapter 7. Cell and Gene Therapy CDMO Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. North America
  • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key Country Dynamics
    • 7.5.1.2. Competitive Scenario
    • 7.5.1.3. Regulatory Framework
    • 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
  • 7.5.2. Germany
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
  • 7.5.3. France
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
  • 7.5.4. Italy
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
  • 7.5.5. Spain
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
  • 7.5.6. Denmark
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
  • 7.5.7. Sweden
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
  • 7.5.8. Norway
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key Country Dynamics
    • 7.6.1.2. Competitive Scenario
    • 7.6.1.3. Regulatory Framework
    • 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
  • 7.6.2. India
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
  • 7.6.4. South Korea
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
  • 7.6.6. Thailand
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key Country Dynamics
    • 7.7.1.2. Competitive Scenario
    • 7.7.1.3. Regulatory Framework
    • 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
  • 7.7.2. Mexico
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key Country Dynamics
    • 7.8.1.2. Competitive Scenario
    • 7.8.1.3. Regulatory Framework
    • 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
  • 7.8.3. UAE
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
  • 7.8.4. Kuwait
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
  • 8.1.1. Innovators
  • 8.1.2. Market Leaders
  • 8.1.3. Emerging Players
  • 8.1.4. Company Market Share Analysis, 2023
• 8.2. Company Profiles
  • 8.2.1. Lonza
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Financial Performance
    • 8.2.1.3. Service Benchmarking
    • 8.2.1.4. Strategic Initiatives
  • 8.2.2. Catalent, Inc
    • 8.2.2.1. Company Overview
    • 8.2.2.2. Financial Performance
    • 8.2.2.3. Service Benchmarking
    • 8.2.2.4. Strategic Initiatives
  • 8.2.3. Cytiva
    • 8.2.3.1. Company Overview
    • 8.2.3.2. Financial Performance
    • 8.2.3.3. Service Benchmarking
    • 8.2.3.4. Strategic Initiatives
  • 8.2.4. Samsung Biologics
    • 8.2.4.1. Company Overview
    • 8.2.4.2. Financial Performance
    • 8.2.4.3. Service Benchmarking
    • 8.2.4.4. Strategic Initiatives
  • 8.2.5. Thermo Fisher Scientific Inc.
    • 8.2.5.1. Company Overview
    • 8.2.5.2. Financial Performance
    • 8.2.5.3. Service Benchmarking
    • 8.2.5.4. Strategic Initiatives
  • 8.2.6. Novartis AG
    • 8.2.6.1. Company Overview
    • 8.2.6.2. Financial Performance
    • 8.2.6.3. Service Benchmarking
    • 8.2.6.4. Strategic Initiatives
  • 8.2.7. WuXi AppTec
    • 8.2.7.1. Company Overview
    • 8.2.7.2. Financial Performance
    • 8.2.7.3. Service Benchmarking
    • 8.2.7.4. Strategic Initiatives
  • 8.2.8. AGC Biologics
    • 8.2.8.1. Company Overview
    • 8.2.8.2. Financial Performance
    • 8.2.8.3. Service Benchmarking
    • 8.2.8.4. Strategic Initiatives
  • 8.2.9. OmniaBio
    • 8.2.9.1. Company Overview
    • 8.2.9.2. Financial Performance
    • 8.2.9.3. Service Benchmarking
    • 8.2.9.4. Strategic Initiatives
  • 8.2.10. Rentschler Biopharma SE
    • 8.2.10.1. Company Overview
    • 8.2.10.2. Financial Performance
    • 8.2.10.3. Service Benchmarking
    • 8.2.10.4. Strategic Initiatives
  • 8.2.11. Charles River Laboratories
    • 8.2.11.1. Company Overview
    • 8.2.11.2. Financial Performance
    • 8.2.11.3. Service Benchmarking
    • 8.2.11.4. Strategic Initiatives